Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of FZ002 for moderate to severe glabellar lines
CTR20261372Phase 2Active
- Sponsor
- Hebei Fengzhang Biological Technology
- Start
- Apr 2026
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, double-blind trial of JHM03 in glabellar furrowing (2 cohorts), sponsored by Hebei Fengzhang Biological Technology. Started Apr 2026; status: active.
02
Drugs
JHM03
03
Conditions
glabellar furrowing
Beyond the preview
Go deeper on CTR20261372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261372.